- Home
- PEN vs IONS Comparison
PEN vs IONS Comparison
Compare PEN & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PEN
- IONS
- Stock Information
- Founded
- PEN 2004
- IONS 1989
- Country
- PEN United States
- IONS United States
- Employees
- PEN N/A
- IONS N/A
- Industry
- PEN Medical/Dental Instruments
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- PEN Health Care
- IONS Health Care
- Exchange
- PEN Nasdaq
- IONS Nasdaq
- Market Cap
- PEN 7.0B
- IONS 6.0B
- IPO Year
- PEN 2015
- IONS 1991
- Fundamental
- Price
- PEN $243.19
- IONS $36.17
- Analyst Decision
- PEN Buy
- IONS Buy
- Analyst Count
- PEN 15
- IONS 18
- Target Price
- PEN $259.86
- IONS $62.00
- AVG Volume (30 Days)
- PEN 337.8K
- IONS 1.7M
- Earning Date
- PEN 10-30-2024
- IONS 02-19-2025
- Dividend Yield
- PEN N/A
- IONS N/A
- EPS Growth
- PEN N/A
- IONS N/A
- EPS
- PEN 0.89
- IONS N/A
- Revenue
- PEN $1,163,776,000.00
- IONS $803,067,000.00
- Revenue This Year
- PEN $13.65
- IONS N/A
- Revenue Next Year
- PEN $14.38
- IONS $19.61
- P/E Ratio
- PEN $273.90
- IONS N/A
- Revenue Growth
- PEN 16.96
- IONS 30.57
- 52 Week Low
- PEN $148.00
- IONS $33.33
- 52 Week High
- PEN $277.34
- IONS $54.44
- Technical
- Relative Strength Index (RSI)
- PEN 51.31
- IONS 41.84
- Support Level
- PEN $235.76
- IONS $36.39
- Resistance Level
- PEN $251.28
- IONS $38.90
- Average True Range (ATR)
- PEN 7.13
- IONS 1.52
- MACD
- PEN -1.55
- IONS -0.08
- Stochastic Oscillator
- PEN 25.79
- IONS 6.61
About PEN Penumbra Inc.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024.